🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Colorado
Clinical trial register · United States · industry-sponsored

Clinical Trials in Colorado, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9119 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:16 UTC
9119
Studies in scope
industry-sponsored, all four open statuses
4952
Recruiting now
open to new participants
2205
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4401 Illinois 2480 Georgia 2350 Arizona 2233
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca88 Janssen Research & Development, LLC69 Eli Lilly and Company65 Merck Sharp & Dohme LLC64 Novartis Pharmaceuticals56
State
California5301 Florida4401 Illinois2480 Georgia2350 Arizona2233
All 51 states
Target enrolment
to

Trials with a site in Colorado

2068 of 9119 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2024-10-14
Recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT06447168Primary Biliary Cholangitis
Ipsen
Observational
424
California, Colorado, Connecticut, Florida, Massachusetts, New Jersey, New York, North Carolina
2024-10-14
Active, closed
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564Chronic Graft-versus-host-disease
DrugsAxatilimab·Ruxolitinib
Incyte Corporation
Phase 2
130
Arizona, California, Colorado, Connecticut, Florida, Illinois, Maryland, Missouri
2024-10-11
Recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic
DrugMirikizumab
Eli Lilly and Company
Phase 2
143
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2024-10-10
Active, closed
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060Episodic Migraine, Chronic Migraine
DrugCorabotase
Ipsen
Phase 2
670
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Louisiana
2024-10-10
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
NCT06630286HIV-1-infection
DrugsISL/LEN·B/F/TAF
Gilead Sciences
Phase 3
609
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-09
Recruiting
Study of ACR-2316 in Specific Advanced Solid Tumors
NCT06667141Specific Advanced Solid Tumors
Acrivon Therapeutics
Phase 1/2
100
Arizona, California, Colorado, Florida, Massachusetts, Michigan, New York, North Carolina
2024-10-08
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
NCT06630299HIV-1-Infection
DrugISL/LEN
Gilead Sciences
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-08
Active, closed
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055SARS-CoV2, COVID-19
DrugComirnaty
Vaxart
Phase 2
5,485
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-08
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386Non-small Cell Lung Cancer
DrugsRelatlimab·Nivolumab·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2024-10-07
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
744
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kentucky
2024-10-04
Active, closed
A Study of RhinAer Stylus for Treating Chronic Rhinitis
NCT06599736Chronic Rhinitis
Aerin Medical
Not applicable
25
Colorado, Ohio
2024-10-03
Recruiting
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473Advanced Solid Tumors
DrugTislelizumab
BeOne Medicines
Phase 1
310
Arizona, California, Colorado, Connecticut, Illinois, Kansas, Mississippi, New Jersey
2024-10-03
Recruiting
ALTO-100 in Bipolar Disorder With Depression (BD-D)
NCT06656416Bipolar Disorder I or II With a Major Depressive Episode
Alto Neuroscience
Phase 2
200
Arizona, Arkansas, California, Colorado, Florida, Georgia, Maryland, Nebraska
2024-10-02
Recruiting
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374Intermediate Risk Non-Muscle Invasive Bladder Cancer
DrugNadofaragene Firadenovec
Ferring Pharmaceuticals
Phase 3
454
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2024-10-01
Recruiting
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
NCT06634394Acute Myeloid Leukemia (AML)
DrugsAzacitidine·Venetoclax
Aptevo Therapeutics
Phase 1
39
Colorado, Florida, Kansas, Ohio, Texas
2024-10-01
Recruiting
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
DrugsNadofaragene Firadenovec·Gemcitabine·Pembrolizumab·Paclitaxel
Ferring Pharmaceuticals
Phase 3
250
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-01
Recruiting
Infant Formula in Infants and Children With Cow's Milk Allergy
NCT06456541Cow's Milk Allergy
Abbott Nutrition
Not applicable
96
Arizona, Colorado, Illinois, Michigan, North Carolina, Ohio, Texas
2024-10-01
Active, closed
SIMPLAAFY Clinical Trial
NCT06521463Atrial Fibrillation, Stroke, Bleeding
Boston Scientific Corporation
Not applicable
1,857
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-01
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
NCT06628908Diabetic Peripheral Neuropathic Pain
DrugsSuzetrigine·Pregabalin
Vertex Pharmaceuticals Incorporated
Phase 3
1,100
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-10-01
Active, closed
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779Severe Asthma
AstraZeneca
Phase 3
326
California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas
2024-09-30
Recruiting
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
NCT06551142Neoplasms
DrugsRis-Rez·Tarlatamab·Dostarlimab·Atezolizumab
GlaxoSmithKline
Phase 1
845
California, Colorado, Connecticut, Indiana, Massachusetts, Michigan, New Jersey, South Carolina
2024-09-30
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
DrugLunsekimig
Sanofi
Phase 2
900
Arizona, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri, North Carolina
2024-09-30
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616Breast Cancer
DrugsElacestrant·Tamoxifen·Anastrozole·Exemestane
Stemline Therapeutics, Inc.
Phase 3
4,220
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-09-27
Recruiting
Registry for Stage 2 Type 1 Diabetes
NCT06481904Type 1 Diabetes
Sanofi
Observational
200
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-09-27
Recruiting
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
NCT06462235Gram-negative Bacterial Infection
Pfizer
Phase 2
48
California, Colorado, Indiana, Kentucky, Massachusetts, North Carolina, Texas
2024-09-25
Active, closed
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394Dravet Syndrome
DrugLP352
Longboard Pharmaceuticals
Phase 3
96
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland
2024-09-25
Active, closed
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
NCT06592794Acute Gastroenteritis, Norovirus Acute Gastroenteritis
DrugMRNA-1403
ModernaTX, Inc.
Phase 3
37,864
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2024-09-24
Active, closed
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
NCT06504446Refractory or Unexplained Chronic Cough
Nocion Therapeutics
Phase 2
455
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-09-24
Active, closed
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027Parkinson Disease
Cerevance
Phase 3
330
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas
2024-09-20
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 1
340
California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Tennessee
2024-09-19
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
NiKang Therapeutics, Inc.
Phase 1
150
Arkansas, California, Colorado, Florida, Georgia, Kansas, Massachusetts, New Jersey
2024-09-19
Active, closed
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814Duchenne Muscular Dystrophy
NS Pharma, Inc.
Phase 1/2
20
California, Colorado, Illinois, Kansas, Pennsylvania
2024-09-18
Active, closed
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951Melanoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
151
California, Colorado, Connecticut, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2024-09-18
Recruiting
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
NCT06398626Colitis, Ulcerative
DrugEtrasimod
Pfizer
Observational
300
Arizona, California, Colorado, Florida, Illinois, Maryland, New Jersey, New York
2024-09-17
Active, closed
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer
DrugsAnvumetostat·Sotorasib·Pemetrexed·Carboplatin
Amgen
Phase 1
49
California, Colorado, Connecticut, Minnesota, Missouri, Nevada, New York, Oklahoma
2024-09-17
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
400
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-09-17
Active, closed
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
NCT06615557Social Anxiety Disorder (SAD)
VistaGen Therapeutics, Inc.
Phase 3
238
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2024-09-16
Recruiting
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743High-Risk Non-Muscle-Invasive Bladder Cancer
DrugCretostimogene Grenadenorepvec
CG Oncology, Inc.
Phase 2
325
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-09-16
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Nab-paclitaxel·Oxaliplatin
Eli Lilly and Company
Phase 1
630
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-09-12
Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150Non-cystic Fibrosis Bronchiectasis
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase 2
284
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Indiana, Iowa
2024-09-11
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland
2024-09-11
Recruiting
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
NCT06379789Hemophilia B
Regeneron Pharmaceuticals
Phase 1/2
130
California, Colorado, Connecticut, Florida, Indiana, Louisiana, Michigan, Ohio
2024-09-11
Recruiting
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916Melanoma
DrugsFianlimab·Relatlimab·Cemiplimab·Nivolumab
Regeneron Pharmaceuticals
Phase 3
560
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-09-09
Recruiting
Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures
NCT06477172Post Procedural Erythema
Acorn Biolabs Inc.
Observational
500
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Michigan
2024-09-09
Active, closed
Amplitude Vascular Systems (AVS) Lithotripsy POWER PAD 2 Trial
NCT06457685Peripheral Arterial Disease (PAD)
Amplitude Vascular Systems, Inc.
Not applicable
115
Arkansas, California, Colorado, Georgia, Iowa, Missouri, New Jersey, New York
2024-09-05
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
DrugsTrosunilimab·Lutikizumab·Risankizumab
AbbVie
Phase 2
540
Alabama, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2024-09-04
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-09-04
Active, closed
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
NCT06616974Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Tectonic Therapeutic
Phase 2
191
Arizona, California, Colorado, Florida, Georgia, Idaho, Kentucky, Maryland
2024-09-04
Recruiting
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
NCT06445608Coronary Artery Disease
Kardion Inc
Not applicable
310
Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Indiana, Massachusetts
2024-09-03
Recruiting
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
NCT06576271Systemic Lupus Erythematosus
DrugBelimumab
GlaxoSmithKline
Phase 1
142
Arizona, Colorado, Nevada, Ohio, Oklahoma, Texas
2024-09-02
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142Immunoglobulin A Nephropathy
DrugPovetacicept
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Idaho
2024-08-30
Active, closed
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
DrugEmpagliflozin
Boehringer Ingelheim
Phase 3
11,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-08-30
Active, closed
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772Coeliac Disease, Celiac Disease
DrugAmlitelimab
Sanofi
Phase 2
229
Arizona, California, Colorado, Florida, Idaho, Kansas, Massachusetts, Michigan
2024-08-29
Recruiting
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT06582017Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
Nammi Therapeutics Inc
Phase 1
100
California, Colorado, Georgia, New York, Texas, Wisconsin
2024-08-28
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
DrugsSacituzumab Govitecan·Doxorubicin·Paclitaxel
Gilead Sciences
Phase 3
640
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-08-28
Recruiting
First In Human Study of CX-801 in Advanced Solid Tumors
NCT06462794Solid Tumor, Adult
DrugPembrolizumab
CytomX Therapeutics
Phase 1
121
California, Colorado, Pennsylvania, Tennessee, Texas
2024-08-28
Recruiting
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
NCT06565195Parkinson's Disease
Prevail Therapeutics
Phase 1
124
Colorado, Connecticut, Florida, Illinois, Michigan, Pennsylvania, Texas
2024-08-27
Recruiting
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
NCT06500884Multiple Myeloma
DrugsRamantamig·Talquetamab
Janssen Research & Development, LLC
Phase 2
210
California, Colorado, Connecticut, New York, North Carolina, Ohio, Virginia, Washington
2024-08-26
Active, closed
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06572228Asthma
DrugsIcs-Laba·Dupilumab
Regeneron Pharmaceuticals
Phase 4
120
California, Colorado, Florida, Idaho, Illinois, Kansas, Kentucky, Maine
2024-08-26
Active, closed
Cancer Prevention for Young Rural Adults
NCT05618158Cancer
Klein Buendel, Inc.
Not applicable
1,796
Arizona, Colorado, New Mexico, Utah
2024-08-26
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin
BioNTech SE
Phase 2
83
California, Colorado, Connecticut, Illinois, Minnesota, New Jersey, New York, Tennessee
2024-08-26
Active, closed
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368Wet Age-related Macular Degeneration
DrugsTabirafusp tedromer·Eylea·Aflibercept
Kodiak Sciences Inc
Phase 3
675
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-08-23
Recruiting
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT06362369Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
DrugsIpilimumab·Nivolumab
7 Hills Pharma, LLC
Phase 1/2
126
Colorado, Florida, New Hampshire, Rhode Island, Texas
2024-08-23
Active, closed
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498Multiple Myeloma
DrugsAnitocabtagene-autoleucel·Carfilzomib·Bortezomib·Pomalidomide
Kite, A Gilead Company
Phase 3
452
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-08-23
Recruiting
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
NCT06415487Locally Advanced Solid Tumor, Metastatic Solid Tumor
DrugsFludarabine·Cyclophosphamide·Pembrolizumab
Acepodia Biotech, Inc.
Phase 1
30
California, Colorado, Tennessee, Texas
2024-08-22
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia
2024-08-22
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
DrugsRiliprubart·IVIG
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas
2024-08-21
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2024-08-16
Active, closed
CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin
NCT06601166Type 2 Diabetes
DexCom, Inc.
Not applicable
283
Colorado, Florida, Georgia, Indiana, Minnesota, Missouri, New York, North Carolina
2024-08-15
Recruiting
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
NCT05861999Muscular Atrophy, Spinal
DrugRisdiplam
Hoffmann-La Roche
Phase 4
28
Arkansas, California, Colorado, Florida, Georgia, Michigan, Pennsylvania, Texas
2024-08-14
Active, closed
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
NCT06496620COPD
DrugSolrikitug
Uniquity One (UNI)
Phase 2
182
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-08-14
Recruiting
SMP-3124LP in Adults With Advanced Solid Tumors
NCT06526819Solid Tumor
Sumitomo Pharma America, Inc.
Phase 1/2
120
California, Colorado, Florida, Illinois, Ohio, Tennessee, Texas, Washington
2024-08-14
Active, closed
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Lenalidomide·Rituximab·Oxaliplatin
Genmab
Phase 3
379
California, Colorado, Georgia, Illinois, Indiana, Kansas, Kentucky, Maryland
2024-08-13
Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429Metastatic HER2-positive Breast Cancer
DrugsZanidatamab·Vinorelbine·Eribulin·Trastuzumab
Jazz Pharmaceuticals
Phase 3
550
Arizona, California, Colorado, District of Columbia, Florida, Massachusetts, Minnesota, Missouri
2024-08-13
Active, closed
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
NCT06524375Chronic Lymphocytic Leukemia
DrugVenetoclax
Genentech, Inc.
Phase 2
118
Arkansas, Colorado, Florida, Indiana, Iowa, Maryland, Massachusetts, Nebraska
2024-08-09
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
110
California, Colorado, Connecticut, Illinois, Indiana, Massachusetts, Minnesota, New York
2024-08-08
Active, closed
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06571045Diabetic Macular Edema (DME)
DrugsEYE103·Ranibizumab
EyeBiotech Ltd.
Phase 2/3
984
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Iowa
2024-08-07
Recruiting
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
NCT06292780Relapsed/Refractory Systemic Light Chain Amyloidosis
DrugLinvoseltamab
Regeneron Pharmaceuticals
Phase 1/2
220
California, Colorado, Massachusetts, Michigan, New York, Ohio, Tennessee, Texas
2024-08-07
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
DrugsSurovatamig·R-Chop
AstraZeneca
Phase 3
1,018
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2024-08-07
Recruiting
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT06428019Chronic Lymphocytic Leukemia
DrugsAcalabrutinib·Obinutuzumab·Venetoclax
AbbVie
Phase 3
170
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Iowa
2024-08-05
Recruiting
VTP-1000 in Adults With Celiac Disease
NCT06310291Celiac Disease
Barinthus Biotherapeutics
Phase EARLY_PHASE1
45
California, Colorado, Florida, Maryland, Michigan, Minnesota, New York, North Carolina
2024-08-01
Recruiting
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
NCT06568367Excessive Sleepiness, Shift-work Disorder
DrugSolriamfetol
Axsome Therapeutics, Inc.
Phase 3
520
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-08-01
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsCamizestrant·Saruparib·Anastrozole·Exemestane
AstraZeneca
Phase 3
788
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Maryland
2024-08-01
By invitation
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
NCT06475742Lupus Erythematosus, Systemic
DrugCenerimod
Viatris Innovation GmbH
Phase 3
680
Colorado, Florida, Louisiana, Nevada, Texas
2024-07-30
Active, closed
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816Geographic Atrophy
DrugVonaprument
Annexon, Inc.
Phase 3
659
Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois, Iowa
2024-07-30
By invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463Focal Epilepsy
DrugBHV-7000
Biohaven Therapeutics Ltd.
Phase 2
660
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-07-30
Active, closed
A Study to Evaluate Solriktug in Adult Participants With Asthma
NCT06496607Asthma
Uniquity One (UNI)
Phase 2
145
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-07-26
Recruiting
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306Depressive Disorder, Major
DrugSeltorexant
Janssen Research & Development, LLC
Phase 3
752
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-07-25
Active, closed
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT06547216FSHD, FSHD1, FSHD2, FMD
DrugDel-brax
Avidity Biosciences, Inc.
Phase 2
84
California, Colorado, Florida, Georgia, Kansas, New York, North Carolina, Ohio
2024-07-25
Recruiting
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
NCT06386146Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Colorado, Florida, Missouri, Ohio, Tennessee, Texas
2024-07-24
Active, closed
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
NCT06491914Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
DrugAflibercept
Regeneron Pharmaceuticals
Phase 3
1,126
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland
2024-07-24
Active, closed
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
NCT06355531Progressive Supranuclear Palsy
Ferrer Internacional S.A.
Phase 2
241
California, Colorado, Florida, Georgia, Massachusetts, Michigan, New York, North Carolina
2024-07-23
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752Relapsing Multiple Sclerosis, Multiple Sclerosis
TG Therapeutics, Inc.
Observational
2,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-07-22
Active, closed
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
NCT06384261Leukemia, Myeloid, Acute
DrugsCusatuzumab·Azacitidine·Venetoclax
OncoVerity, Inc.
Phase 2
140
Arizona, California, Colorado, Connecticut, Florida, Iowa, Kentucky, New Jersey
2024-07-22
Active, closed
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003Severe Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
446
California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland, Michigan
2024-07-22
Recruiting
QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
NCT06517810Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
SeaStar Medical
Observational
50
Alabama, California, Colorado, Georgia, Illinois, Michigan, Ohio, Pennsylvania
2024-07-19
Active, closed
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
DrugRYZ101
RayzeBio, Inc.
Phase 1/2
16
Arizona, California, Colorado, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-07-19
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
976
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-07-19
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin
Jazz Pharmaceuticals
Phase 3
286
California, Colorado, Florida, Georgia, Kansas, Kentucky, Louisiana, Massachusetts
2024-07-19
Rows per page Showing 801–900 of 2068
Previous 7 8 9 10 11 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-usa/state/colorado?page=9

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,119 studies in total at the last sync on 25 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,068 of those studies with a site in Colorado.

How many clinical trials are recruiting in Colorado?

1,024 of the 2,068 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:16 UTC sync. A further 29 have not yet opened recruitment, 950 are active but closed to new participants, and 65 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.